Y. Eugene Chen

New Capabilities

As of July 2026: Leading DT-109 development toward human trials

Severe fatty liver disease has almost no drugs that reverse it. On July 11, 2026, a University of Michigan team reported that an experimental compound called DT-109 did exactly that in mice and monkeys, by fixing the gut instead of the liver.

Updated Jul 11